Search
Cinchophen
go.drugbank.com/drugs/DB13551ExperimentalCategories: Preparations With No Effect on Uric Acid MetabolismDFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.
G4544
go.drugbank.com/drugs/DB05244ExperimentalG4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite⢠(gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabo...
Arylacenamide
go.drugbank.com/drugs/DB05792ExperimentalArylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
MD05
go.drugbank.com/drugs/DB06375InvestigationalMD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...
Terevalefim
go.drugbank.com/drugs/DB16397InvestigationalTerevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).